Navigation Links
Don't Know How Much an X-Ray Costs You? Highmark Network Providers Will Begin Having Conversations With Highmark Members About Their Actual Cost of Care
Date:12/1/2008

Real-time capabilities support providers in discussing health care costs

PITTSBURGH, Dec. 1 /PRNewswire/ -- As health care costs continue to rise, many employers have shifted more of the cost of health care to their employees through higher premiums or cost-sharing on their benefit programs with deductibles and coinsurance. To help consumers better understand their actual cost of health care, Highmark providers, such as primary care physicians, specialists, health care facilities and hospitals, now have tools to assist them in discussions with Highmark members about their out-of-pocket costs. Highmark is the first insurer in the region to roll out real-time capabilities, which gives providers the ability to set payment expectations with members. With real-time capabilities, providers can send an electronic claim to Highmark and receive a response indicating the amount the Highmark member owes. Providers can use these tools prior to service or at the point of service, and then have the option to collect this payment or make payment arrangements with the member at the time services are received.

For example, if a Highmark member were scheduled to receive an x-ray, the provider could use Highmark's real-time capabilities to estimate the cost of the x-ray to the member taking in to account their specific health benefit design including deductibles and coinsurance. The member would then have a clear understanding of their financial responsibility for the service and would be prepared to make any necessary payments to the provider.

These real-time capabilities allow Highmark members with high deductibles, coinsurance or other types of cost-sharing to better understand the actual cost of health care services. Approximately 730,000 Highmark members in Pennsylvania are currently enrolled in health plans with cost-sharing that includes deductibles and/or coinsurance for in-network services.

<
'/>"/>
SOURCE Highmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Dental Implants Effective for Orthodontic Treatment
2. Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association
3. Orthodontists Offer Sweet Incentives for Tricky Halloween Treats
4. Ortho Organizers(R) Opens a Full-Service Orthodontic Laboratory
5. Researchers report periodontal disease independently predicts new onset diabetes
6. Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM)
7. Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment
8. Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients
9. Saving teeth by using periodontal ligament regeneration
10. Ortho Organizers(R) Introduces New Premium Product Line - O2 Select(TM) Orthodontic Instruments
11. HPV, periodontitis work in tandem to increase risk of tongue cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...uot;This is an opportunity for you to change your ...Free pills, you will experience a noticeable relie...d sugar, cholesterol levels and blood pressure wil...and your mind will finally be freed from the healt...atient." , Miami, FL...
(Date:7/2/2009)...aders to Support Principles to Govern Health Insur...ewswire-USNewswire/ -- Nearly nine out of ten vote...ave too much influence over how doctors care for t...pport the concept of a "Health Insurer Code of Con...iples for health insurance companies with respect ...
(Date:7/2/2009)...usinesses honored in Washington, D.C. , , ARLI...Texas Health Resources has received the Best Empl...nal Business Group on Health. , , (Logo: htt...OGO ) , , The award recognizes the nation,s ...promote a healthy workplace and for helping employ...
(Date:7/2/2009)...NA of the hepatitis B virus (HBV) are associated w...redict which patients with HBV infections are at i... meta-analysis in the Journal of the National Can...nfection is a known cause of hepatocellular carcin...revious studies have looked at whether patients wi...
Breaking Medicine News(10 mins):Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 2Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 3Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 2Health News:Texas Health Resources Recognized by National Business Group on Health as Leading Employer Promoting Healthy Lifestyles for Employees 3
...disease can be delayed to a great extent by taking...or impaired blood flow // and leg pain, accordin...erson can also be improved through the exercise. A...ysical ability of 417 men and women by measuring t...
...he University of California have now established a...kidney failure, or end-stage renal disease. So if ...hoes right away, as there is no time to lose. // ...kidney failure, but it hasn't been appreciated muc...
...ly no short cuts to effective weight loss apart fr...search to prove this point, several myths abound /...ely shed the extra weight, and dispel famous myths...equated as input versus output. Weight gain happen...
...ty of Clinical Oncology has chosen 11 research eff... for the year 2005. Prominent// among them is the ...the recurrence of HER-2-positive early-stage breas...g the fact that treatment of early-stage lung canc...
Other Medicine News:Health News:The weight loss reality check – Do Fad diets and short-cut methods actually work 2
(Date:6/30/2009)...PRNewswire/ -- , - "Study Could Have Major ...t to Infertility Treatment" , New data from...,s,European Society of Human Reproduction and Emb...parameters of the simulation model used, the in vi...-purified human menopausal,gonatropin or HP-hMG) ...
(Date:6/29/2009)... achieved primary and secondary endpoints , , R...x Pharmaceuticals, Inc. today announced positive r...uating the safety and efficacy of its ARX-01 Sufen...t-operative pain in patients requiring opioid anal... patients receiving ARX-01 Sufentanil NanoTabs for...
(Date:6/28/2009)...stCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SG... has been achieved in its Research and License Agr... of the Roche Group, for the generation of cell li...protein production purposes using Sangamo,s propri...N) technology. Genentech scientists demonstrated t...
(Date:6/26/2009)...n, June 27, 2009 Takeda Pharmaceut...at Takeda Global Research & Development Center...iary received on June 26 (U.S. time) a complete re...ration (FDA) regarding the Company,s New Drug Appl...yl peptidase IV (DPP-4) inhibitor under investigat...
Breaking Medicine Technology:New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 2New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 3New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF 4AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2Mental and physical exercise delays dementia in fatal genetic disease 10012 1Mental and physical exercise delays dementia in fatal genetic disease 10012 2New Colon Cancer Test Might Spot Trouble Earlier 10007 1New Colon Cancer Test Might Spot Trouble Earlier 10007 2New Colon Cancer Test Might Spot Trouble Earlier 10007 3ZYTO Corp Appoints New Chief Operations Officer and New Chief Financial Officer 10002 1ZYTO Corp Appoints New Chief Operations Officer and New Chief Financial Officer 10002 2Statement by Bruce Bodaken on Senate Health Committee Action 9997 1
...lerated with signs of durable,disease control in a...05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc... II,UVIDEM (IDD-3) melanoma vaccine clinical trial...well tolerated with evidence of,efficacy and induc...ve metastatic melanoma. , The data were presented ...
...ind these data reassuring", PHILADELPHIA, June 05,...id today that findings from an interim analysis,of...mes and,Regulation of glycemia in Diabetes), a pro...etermine cardiovascular outcomes in more,than 4,40...ence to,the overall cardiovascular safety profile ...
Other Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5
The CYPHER Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, s
The eNclose Anastomosis Assist Device was designed specifically to obviate the need for partial clamping of the aorta. The enclose device can provide the surgeon with a stable, bloodless field and im
15mm Open Blades, 30mm Maximum Blade Spread; in Titanium.
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel.
Medicine Products: